Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 28;14:4967–4976. doi: 10.2147/IJGM.S321253

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Liao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ROC curves of HBcrAg and SCALE-B scores to predict clinical relapse after discontinuation of NA therapy. (A) Respective AUCs of HBcrAg for predicting of clinical relapse after NA discontinuation at 1, 3, and 5 years were 0.78 (p < 0.001), 0.71 (p < 0.001) and 0.71 (p<0.001). (B) In stratification analysis EOT HBcrAg level ≥ 4.0 log₁₀ U/mL was associated with a higher risk of clinical relapse (65.8% vs 23.2%, p < 0.001). (C) EOT HBcrAg level ≥ 4.0 log₁₀ U/mL was associated with a higher risk of HBeAg reversion (27.5% vs 1.6%, p < 0.001). (D) Respective AUCs of SCALE-scores for predicting of clinical relapse after NA discontinuation at 1, 3, and 5 years were 0.81 (p < 0.001), 0.74 (p < 0.001) and 0.75 (p<0.001). (E) SCALE-B score < 260 points (22.2%) was associated with a lower risk of clinical relapse, compared to 260–320 points (50%, p < 0.001) and ≥ 320 points (82.2%, p < 0.001). (F) SCALE-B score < 260 points (3.8%) was associated with a lower risk of HBeAg reversion, compared to 260–320 points (18.8%, p < 0.001) and ≥ 320 points (30.4%, p < 0.001).